Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Allarity Therapeutics
Spanish Breast Cancer Research Group
Eastern Cooperative Oncology Group
Baylor College of Medicine
M.D. Anderson Cancer Center
University of Virginia
Dana-Farber Cancer Institute
Takeda
Fundacio Clinic Barcelona
Stanford University
Ottawa Hospital Research Institute
Sanofi
Bolt Biotherapeutics, Inc.
Pfizer
Taiho Oncology, Inc.
University of Southern California
Tempus AI
Incyte Corporation
Zenith Epigenetics
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Georgetown University
Sanofi
Sanofi
SBI ALApharma Canada, Inc.
University of Alabama at Birmingham
Alaunos Therapeutics
Alaunos Therapeutics
Eli Lilly and Company
Hoffmann-La Roche
Washington University School of Medicine
Eli Lilly and Company
Daiichi Sankyo
M.D. Anderson Cancer Center
NRG Oncology
SOLTI Breast Cancer Research Group
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Pfizer
Thomas Jefferson University
NextCure, Inc.
Inova Health Care Services
University of Utah
Elevation Oncology
National Cancer Institute (NCI)
NantBioScience, Inc.
Deciphera Pharmaceuticals, LLC
M.D. Anderson Cancer Center
Wake Forest University Health Sciences